LivaNova enters the post-earnings window with the stock up roughly 4% on the week to $85.33, options traders decisively leaning bullish, and a fresh round of analyst upgrades pushing consensus price targets above the current price for the first time this year.
The sharpest signal this week came from the Street. Needham's Mike Matson raised his target to $93 from $81 on August 5 — the day earnings landed — while maintaining his Buy rating. That follows Mizuho lifting its target to $95 three weeks ago. Both moves sit above the consensus mean of $86. The outlier is Barclays, which has held an Equal-Weight with a $76 target since May, acting as the main brake on the bull narrative. The split captures the debate well: bulls see the aura6000 device pipeline adding meaningful revenue — estimates run from $120 million in 2027 toward $280 million by 2029 under favourable conditions — while bears point to low-single-digit organic growth in the core neuromodulation and cardiovascular segments and the risk that FDA approval timelines slip. Valuation sits at a PE near 17.9x trailing earnings, well below the stretched levels flagged in prior notes, with EV/EBITDA around 11.5x. Neither multiple looks obviously demanding for a med-tech name with LivaNova's growth profile, though earnings surprise has historically been weak, ranking only in the 26th percentile of the universe.
Options positioning flipped noticeably after the earnings release. The put/call ratio jumped to 0.35 on August 4 from a run of sub-0.18 readings through the prior two weeks — not a defensive reading in absolute terms, since the 52-week range spans 0.07 to 3.40, but a meaningful step up from what had been an unusually call-heavy stretch since late July. The z-score relative to the 20-day mean is still under 0.2, so options positioning looks more normalised than alarmed.
Short interest tells a quieter story. Bears hold about 7.3% of the free float — material enough to be notable, but the position has barely moved in a week, falling less than 0.3%. The one-month picture is more interesting: SI climbed roughly 10% over July before stabilising, tracking a period when the stock drifted sideways. Borrow costs remain low at 0.43%, down nearly 20% over the past week. Availability is extremely loose at 895%, near the high end of the range seen all year and well above the 52-week floor of 461%. With that much lending supply available, short sellers face no squeeze pressure — the bears holding their 7.3% position can sit comfortably without the borrow market working against them.
Institutional ownership adds texture. BlackRock holds nearly 13% of shares and added modestly through June. Fidelity (FMR LLC) reported a large new position in May — nearly 2.6 million shares added — making it the third-largest holder at 4.9%. Millennium trimmed sharply in Q1, cutting over a million shares. Those two moves — Fidelity building, Millennium reducing — represent the largest recent institutional flows in either direction and roughly mirror the bull-bear split playing out in analyst recommendations.
The next focal point is how management's updated revenue guidance — the $940–955 million range for the year — lands relative to consensus after today's report. With availability loose, borrow cheap, and the stock trading near the lower end of the analyst target cluster, the key variable is whether the aura6000 pipeline narrative gains or loses credibility over the coming weeks.
See the live data behind this article on ORTEX.
Open LIVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
